Answers are grounded in this paper and cite their sources.
Beimu Gualou Formula (BMGLF) is a traditional Chinese medicine (TCM) formula with the potential to treat chronic obstructive pulmonary disease (COPD). However, the main components and potential mechanisms of BMGLF remain unclear. This study aimed to explore the active ingredients and potential action mechanisms of BMGLF for treating COPD by utilizing network pharmacological analysis. In this study, The TCMSP database was searched for the medicinal chemistry of BMGLF to screen its active ingredients and action targets; the GeneCards database was searched to obtain COPD targets; drug targets and disease targets were intersected and a PPI network was constructed using the String database and Cytoscape 3.9.1 software to obtain key targets.; GO enrichment analysis and KEGG pathway analysis of the intersected targets were performed using David database. A total of 47 active ingredients of BMGLF were found, among which the core components were luteolin, naringenin, beta-sitosterol, and acacetin; 112 intersecting targets of BMGLF for COPD treatment were obtained, among which the core targets were TP53, TNF, CASP3, AKT1, and ESR1, etc. GO analysis yielded 328 entries, and KEGG analysis yielded 151 signals, involving Pathways in cancer, PI3K-Akt signaling pathway, Lipid and atherosclerosis, and so on. This study revealed that BMGLF may act synergistically via multi-components, multi-targets, and multi-pathways for COPD treatment, providing a theoretical basis for further mechanistic studies.
No takes yet. Share an insight, caveat, or question.
Fuwenxuan Ding (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: